NCT06740916View on ClinicalTrials.gov

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin Resistance

PHASE3RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
Myeloproliferative Neoplasms (MPN)
Interventions
DRUG

81-mg aspirin once daily

81-mg aspirin once daily

DRUG

81-mg aspirin twice daily

81-mg aspirin twice daily

Trial Locations (1)

10700

RECRUITING

Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok Noi

All Listed Sponsors
lead

Siriraj Hospital

OTHER